Provided by Tiger Trade Technology Pte. Ltd.

ADC Therapeutics SA

0.9966
+0.03653.80%
Post-market: 0.9900-0.0066-0.66%19:30 EDT
Volume:1.09M
Turnover:1.07M
Market Cap:126.61M
PE:-1.50
High:1.00
Open:0.9740
Low:0.9700
Close:0.9601
52wk High:4.98
52wk Low:0.7796
Shares:127.04M
Float Shares:88.56M
Volume Ratio:0.42
T/O Rate:1.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6636
EPS(LYR):-1.1224
ROE:-705.53%
ROA:-19.57%
PB:-0.55
PE(LYR):-0.89

Loading ...

ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says

MT Newswires Live
·
Aug 14

UK's Akari Therapeutics Q2 Net Loss Widens on Higher R&D for AKTX-101

Reuters
·
Aug 14

ADC Therapeutics SA Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

ADC Therapeutics Sa - Q2 Net Product Revenue of $18.6 Million, Net Loss $0.11 Per Share

THOMSON REUTERS
·
Aug 13

ADC Therapeutics Posts Corporate Presentation Highlighting Zynlonta Growth Opportunity in B-Cell Lymphomas

Reuters
·
Aug 13

ADC Therapeutics Q2 Income from Operations USD -25.414 Million Vs. IBES Estimate USD -24.4 Million

Reuters
·
Aug 13

ADC Therapeutics Q2 FY26 Net Loss Narrows 70.75% to $16.6 Million; Revenue Rises 2.99% to $19.25 Million

Reuters
·
Aug 13

ADC Therapeutics Q2 Operating Expenses USD -44.662 Million

THOMSON REUTERS
·
Aug 13

Press Release: ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

Dow Jones
·
Aug 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 13

ADC Therapeutics SA Expected to Post a Loss of 21 Cents a Share - Earnings Preview

Reuters
·
Aug 11

ADC Therapeutics SA Expected to Post a Loss of 21 Cents a Share - Earnings Preview

Reuters
·
Aug 08

ADC Therapeutics Schedules Second-Quarter Results Conference Call

Reuters
·
Aug 06

These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why

Benzinga_recent_news
·
Jul 22

ADC Therapeutics Grants New Employee Options for 17,000 Shares Under Inducement Plan

Reuters
·
Jul 02

Analysts Are Bullish on Top Healthcare Stocks: ADC Therapeutics (ADCT), Moleculin Biotech (MBRX)

TIPRANKS
·
Jul 02

ADC Therapeutics completes enrollment in Phase 1b Zynlonta trial

TIPRANKS
·
Jun 30

ADC Therapeutics Completes Lotis-7 Phase 1b Enrollment for Zynlonta-glofitamab Combo in R/r DLBCL

Reuters
·
Jun 30

ADC Therapeutics - Full Lotis-7 Data Expected in Q4 2026

THOMSON REUTERS
·
Jun 30

ADC Therapeutics Announces Completion of Enrollment in Lotis-7 Phase 1B Zynlonta® Combination Trial

THOMSON REUTERS
·
Jun 30